Status:

UNKNOWN

Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)

Lead Sponsor:

Manhattan Pharmaceuticals

Conditions:

Obesity

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects.

Eligibility Criteria

Inclusion

  • Be a male or female between the ages of 18 and 65 years, inclusive
  • Female subjects must be either surgically sterile or at least 2 years postmenopausal
  • Have a BMI of 27 - 38.9, inclusive
  • Have a stable weight for the past 30 days per subject report
  • Be otherwise healthy and have an acceptable medical history
  • Have negative urinalysis test results for drugs of abuse and alcohol
  • Have the ability to understand the requirements of the study, have provided written informed consent and agree to abide by the study restrictions
  • Exhibit stable behavior patterns with regard to smoking and exercise
  • Subject who has at least one factor of the metabolic syndrome

Exclusion

  • Be pregnant or nursing
  • Have taken exclusionary medication in the past 30 days
  • Have any clinically significant abnormal laboratory test as determined by the investigator
  • Have a clinically significant illness during the 30 days before enrollment
  • Have a history of testing positive for Hepatitis B virus, Hepatitis C virus, or HIV
  • Have a confirmed diagnosis or history of cancer, with the exception of nonmelanoma skin cancer
  • Have a previous diagnosis of diabetes
  • Be otherwise unsuitable for the study, in the opinion of the investigator
  • Have an allergy to safflower seeds or its byproducts (e.g., safflower oil)
  • Have any postmenopausal bleeding within the last 6 months
  • Have been involved in a formal or informal (self-imposed) diet regimen within the last 30 days
  • Currently working night shifts
  • Have a history of known multiple miscarriages

Key Trial Info

Start Date :

June 1 2006

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00449202

Start Date

June 1 2006

Last Update

March 20 2007

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Pennington Biomedical Research

Baton Rouge, Louisiana, United States, 70808

2

Jean Brown Research

Salt Lake City, Utah, United States, 84124

3

Swiss Pharma Contract

Basel, Switzerland